{"id":1741,"date":"1998-11-01T12:07:00","date_gmt":"1998-11-01T11:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/famciclovir-zur-praevention-des-rekurrierenden-herpes-simplex-genitalis"},"modified":"2022-03-17T14:08:59","modified_gmt":"2022-03-17T13:08:59","slug":"famciclovir-zur-praevention-des-rekurrierenden-herpes-simplex-genitalis","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1998\/famciclovir-zur-praevention-des-rekurrierenden-herpes-simplex-genitalis","title":{"rendered":"Famciclovir zur Pr\u00e4vention des rekurrierenden Herpes simplex genitalis"},"content":{"rendered":"<p>Der Herpes simplex genitalis geh\u00f6rt zu den h\u00e4ufigsten sexuell \u00fcbertragenen Erkrankungen. Serologische Untersuchungen bei Erwachsenen ergeben eine Pr\u00e4valenz des Herpes-simplex-Virus-2 (HSV-2) von etwa 22% in den USA, 7 bis 20% in verschiedenen europ\u00e4ischen L\u00e4ndern und 20 bis 40% in einigen Staaten Afrikas (1). Die meisten Patienten, die bei der Erstinfektion Symptome haben, erleiden rekurrierende Manifestationen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Der Herpes simplex genitalis geh\u00f6rt zu den h\u00e4ufigsten sexuell \u00fcbertragenen Erkrankungen. Serologische Untersuchungen bei Erwachsenen ergeben eine Pr\u00e4valenz des Herpes-simplex-Virus-2 (HSV-2) von etwa 22% in den USA, 7 bis 20% in verschiedenen europ\u00e4ischen L\u00e4ndern und 20 bis 40% in einigen Staaten Afrikas (1). Die meisten Patienten, die bei der Erstinfektion Symptome haben, erleiden rekurrierende Manifestationen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[3630,3629,3904,411,3628],"class_list":["post-1741","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-aciclovir","tag-famciclovir","tag-herpes-simplex-genitalis","tag-penciclovir","tag-valaciclovir"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1741","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1741"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1741\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1741"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1741"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1741"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}